Cargando…
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retros...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067800/ https://www.ncbi.nlm.nih.gov/pubmed/33917093 http://dx.doi.org/10.3390/jcm10081551 |
_version_ | 1783682887449575424 |
---|---|
author | Bodro, Marta Cofan, Frederic Ríos, Jose Herrera, Sabina Linares, Laura Marcos, María Angeles Soriano, Alex Moreno, Asunción Diekmann, Fritz |
author_facet | Bodro, Marta Cofan, Frederic Ríos, Jose Herrera, Sabina Linares, Laura Marcos, María Angeles Soriano, Alex Moreno, Asunción Diekmann, Fritz |
author_sort | Bodro, Marta |
collection | PubMed |
description | In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed. |
format | Online Article Text |
id | pubmed-8067800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80678002021-04-25 Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 Bodro, Marta Cofan, Frederic Ríos, Jose Herrera, Sabina Linares, Laura Marcos, María Angeles Soriano, Alex Moreno, Asunción Diekmann, Fritz J Clin Med Article In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed. MDPI 2021-04-07 /pmc/articles/PMC8067800/ /pubmed/33917093 http://dx.doi.org/10.3390/jcm10081551 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bodro, Marta Cofan, Frederic Ríos, Jose Herrera, Sabina Linares, Laura Marcos, María Angeles Soriano, Alex Moreno, Asunción Diekmann, Fritz Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title | Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_full | Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_fullStr | Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_full_unstemmed | Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_short | Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_sort | use of anti-cytokine therapy in kidney transplant recipients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067800/ https://www.ncbi.nlm.nih.gov/pubmed/33917093 http://dx.doi.org/10.3390/jcm10081551 |
work_keys_str_mv | AT bodromarta useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT cofanfrederic useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT riosjose useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT herrerasabina useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT linareslaura useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT marcosmariaangeles useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT sorianoalex useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT morenoasuncion useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT diekmannfritz useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 |